-transparent.png){kind=logo}
In a phase I study, the bacterial vaccine OK-432 (streptococcus pyogenes) was investigated in eight patients with advanced malignant tumors. Besides a fever reaction after i.v. application no toxic side effects were observed. Additionally, its therapeutic effectiveness could be demonstrated by i.v. and local therapy. There was also observed an increase of lymphocyte blastogenesis response in patients under treatment with OK-432.
Related Publications
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
October 1994,
Cancer immunology, immunotherapy : CII,
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
July 1984,
Nihon Gan Chiryo Gakkai shi,
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
December 1982,
The Keio journal of medicine,
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
October 1990,
Medical hypotheses,
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
January 1990,
Biotherapy (Dordrecht, Netherlands),
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
April 1982,
Nihon Gan Chiryo Gakkai shi,
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
January 1980,
Microbiology and immunology,
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
January 2009,
BMC immunology,
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
October 1980,
International journal of cancer,
M Micksche, and
E M Kokoschka, and
P Sagaster, and
K Kofler
January 1990,
Biotherapy (Dordrecht, Netherlands),
